Get the Stockscreener App
9.31
6.64%
0.58
After Hours:
9.10
-0.21
-2.26%
Prothena Corporation Plc stock is traded at $9.31, with a volume of 543.66K.
It is up +6.64% in the last 24 hours and up +4.84% over the past month.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
See More
Previous Close:
$8.73
Open:
$8.84
24h Volume:
543.66K
Relative Volume:
0.97
Market Cap:
$501.19M
Revenue:
$9.68M
Net Income/Loss:
$-244.09M
P/E Ratio:
-2.0531
EPS:
-4.5346
Net Cash Flow:
$-168.85M
1W Performance:
+8.38%
1M Performance:
+4.84%
6M Performance:
-0.53%
1Y Performance:
-26.40%
1-Day Range:
$8.82
$9.315
1-Week Range:
$8.3775
$9.315
52-Week Range:
$4.32
$13.52
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
9.31 | 469.96M | 9.68M | -244.09M | -168.85M | -4.5346 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Dow Update: Will Prothena Corporation plc benefit from rising consumer demandEntry Point & Low Risk High Reward Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Prothena stock rating on Parkinson’s data By Investing.com - Investing.com UK
Prothena Q4 earnings meet estimates, pipeline progress in focus - MSN
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Prothena Corp plc stock gains spotlight as partners Roche and Bristol-Myers Squibb showcase key clin - AD HOC NEWS
Prothena Partners Present Data Supporting Next Generation Treatme - The National Law Review
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 - FinancialContent
Prothena Corp plc stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Prothena authorizes up to $100 million share repurchase plan - MSN
Avoiding Lag: Real-Time Signals in (PRTA) Movement - Stock Traders Daily
Earnings Update: Will Prothena Corporation plc outperform its industry peers2026 Major Catalysts & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
History Review: Is Prothena Corporation plc attractive for institutional investors2026 Volume Leaders & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Biotech Headwinds Amid Pipeline Delays - AD HOC NEWS
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Headwinds Amid Biotech Volatility - AD HOC NEWS
Prothena Corporation plc $PRTA Stake Lessened by Prosight Management LP - MarketBeat
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility - AD HOC NEWS
Citizens reaffirms Prothena stock rating on Novo Nordisk milestone By Investing.com - Investing.com South Africa
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Pressure Amid Biotech Volatility - AD HOC NEWS
Prothena earns $50M milestone from Novo Nordisk for drug trial - Investing.com Nigeria
IPO Launch: Will Prothena Corporation plc outperform tech stocks2026 Movers & Weekly High Return Forecasts - baoquankhu1.vn
Prothena (NASDAQ:PRTA) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Discipline and Rules-Based Execution in PRTA Response - Stock Traders Daily
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related t - PharmiWeb.com
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena Corporation Plc Receives $50 Million Clinical Milestone Payment From Novo Nordisk - marketscreener.com
Prothena earns $50M milestone from Novo Nordisk for drug trial By Investing.com - Investing.com South Africa
PRTA Earnings History & Surprises | EPS & Revenue Results | PROTHENA CORP PLC (NASDAQ:PRTA) - ChartMill
Is Prothena Corporation plc stock a dividend growth opportunity2025 Buyback Activity & Real-Time Buy Zone Alerts - Naître et grandir
Aug Reactions: Is Prothena Corporation plc attractive for institutional investors - baoquankhu1.vn
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA) - Seeking Alpha
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Finviz
Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Prothena Announces $100 Million Share Repurchase Program - The Globe and Mail
Prothena Corporation plc (PRTA) Stock Analysis: Navigating a 137% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Prothena authorizes $100 million share buyback program - Investing.com South Africa
Prothena Corporation plc announces an Equity Buyback for $100 million worth of its shares. - marketscreener.com
Prothena (NASDAQ: PRTA) okays $100M share buyback through 2026 - Stock Titan
Prothena Approves $100 Million Share Buyback Authorization - marketscreener.com
Prothena stock jumps on $100M share buyback authorization By Investing.com - Investing.com UK
Prothena Corporation plc (NASDAQ: PRTA) clears shelf to sell up to $200M in shares - Stock Titan
Prothena Announces up to $100 Million Share Repurchase Plan - The Joplin Globe
PROTHENA CORP PUBLIC LTD CO SEC 10-K Report - TradingView
Prothena (NASDAQ: PRTA) reshapes pipeline and cuts staff in 10-K - Stock Titan
Prothena Corporation plc authorizes a Buyback Plan. - marketscreener.com
Behavioral Patterns of PRTA and Institutional Flows - Stock Traders Daily
FY2026 EPS Estimates for Prothena Boosted by HC Wainwright - MarketBeat
Royal Bank Of Canada Increases Prothena (NASDAQ:PRTA) Price Target to $12.00 - Defense World
RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12. - GuruFocus
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):